An Arizona veteran given just six to 12 months to live is defying the odds after undergoing awake brain surgery, talking through the entire procedure so doctors could carve out as much of his tumor as possible without damaging his ability to speak. Kyle Fischer's ordeal began in February 2023, when he lost vision in one eye and started getting frequent headaches that wouldn't let up.
Those symptoms led to a diagnosis of stage 4 brain cancer, according to FOX 10 Phoenix, which first reported on Fischer's case. Doctors told him he likely had somewhere between six months and a year left. Because his tumor sat near the part of the brain that controls speech, surgeons couldn't simply put him under and operate blind to the risk — they needed him conscious and talking the whole time.
Staying Awake to Protect His Voice
During the operation, Fischer continued speaking so the surgical team could gauge, in real time, how much tissue they could safely remove without pushing into territory that would cost him his ability to communicate, per the same FOX 10 report. It's a high-wire balancing act: cut too little and the tumor remains a threat, cut too much and a patient can lose language permanently. For Fischer, that meant staying alert and responsive on the table while surgeons worked around the clock-ticking stakes of his prognosis.
The outcome was better than many might have expected. Fischer's surgery went well, and he was discharged from the hospital just one day later, the station reported. At the time FOX 10 interviewed him, he was still healing from the operation and receiving targeted radiation, with plans in place to travel to Mexico for immunotherapy treatment.
Banking Tumor Cells for a Future Vaccine
Beyond the surgery itself, doctors preserved samples of Fischer's tumor cells, with plans to store them for up to two years in hopes of eventually creating a vaccine tailored specifically to fight his cancer, FOX 10 reported. The approach reflects a broader wave of research into dendritic cell therapy, with numerous clinical trials currently examining the concept, according to the same report.
The science behind that kind of personalized treatment is still evolving but has shown real promise elsewhere. UCLA Health describes its DCVax-L process as one where a patient's own dendritic cells are exposed to proteins pulled from that same patient's tumor, essentially training the immune system to recognize and attack the cancer. UCLA reports that roughly two dozen patients who received the vaccine through clinical trials have gone on to become long-term survivors, and researchers are now investigating whether pairing it with other immunotherapies, including immune checkpoint inhibitors, could produce even stronger results.
Other trials point to similar momentum. A phase 1 study of a different personalized glioblastoma vaccine, GNOS-PV01, treated nine newly diagnosed patients at Siteman Cancer Center, according to LiveNOW from FOX. That vaccine was engineered to target up to 40 tumor-specific proteins per patient — roughly double the number used in earlier cancer vaccines. Among participants in that trial, about two-thirds showed no cancer progression six months after surgery, and a third were still alive two years out, with the findings published May 12 in the journal Nature Cancer.
One of UCLA's own patient stories underscores just how far survival can stretch with this kind of treatment. Jeannine Walston says she was diagnosed with a brain tumor in 1998 at age 24, and went on to schedule her third awake brain surgery in November 2013 before receiving radiation, oral chemotherapy, and the DCVax-L vaccine to treat a Grade III anaplastic astrocytoma. It's worth noting that brain tumors aren't formally assigned numbered stages the way many other cancers are — the Mayo Clinic instead classifies them by grade, with a grade 4 tumor described as one that grows very fast.
For now, Fischer's path forward includes continued healing, ongoing radiation, and the hope that his preserved tumor samples could one day become the basis of a treatment built just for him. Whether that vaccine materializes, and how his health progresses from here, remains to be seen.
